GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Price-to-Tangible-Book
Switch to:

Biogen (MEX:BIIB) Price-to-Tangible-Book

: 6.32 (As of Today)
View and export this data going back to 2013. Start your Free Trial

As of today (2023-04-02), Biogen's share price is MXN4989.94. Biogen's Tangible Book per Share of Dec. 2022 for the quarter that ended in Dec. 2022 was MXN789.88. Hence, Biogen's Price to Tangible Book Ratio of today is 6.32.

The historical rank and industry rank for Biogen's Price-to-Tangible-Book or its related term are showing as below:

MEX:BIIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.2   Med: 6.99   Max: 24.7
Current: 6.9

During the past 13 years, Biogen's highest Price to Tangible Book Ratio was 24.70. The lowest was 0.20. And the median was 6.99.

MEX:BIIB's Price-to-Tangible-Book is ranked worse than
86.39% of 889 companies
in the Drug Manufacturers industry
Industry Median: 2.16 vs MEX:BIIB: 6.90

A closely related ratio is called PB Ratio. As of today, Biogen's share price is MXN4989.94. Biogen's Book Value per Sharefor the quarter that ended in Dec. 2022 was MXN1,824.98. Hence, Biogen's P/B Ratio of today is 2.73.


Biogen Price-to-Tangible-Book Historical Data

The historical data trend for Biogen's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Tangible-Book
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.00 12.98 20.52 11.75 6.84

Biogen Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Price-to-Tangible-Book Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.75 9.18 7.29 7.71 6.84

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Price-to-Tangible-Book Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Biogen's Price-to-Tangible-Book falls in comparison to its industry or sector. The grey bar indicates the Price-to-Tangible-Book's extreme value range as defined by GuruFocus.



Biogen Price-to-Tangible-Book Calculation

Biogen's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2022 )
=4989.94/789.877
=6.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Biogen Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Biogen's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines